Overview
Seelos Biosciences is a clinical-stage company developing intranasal racemic ketamine (SLS-002) for acute suicidal ideation and behavior in major depressive disorder. They have a broader pipeline targeting CNS and rare disease indications.
More in Mental Health Tech
Latest industry news
NIH-Backed Device Gives People With Paralysis a New Path to Communication
2026-10-14 · Research
ABILITY Neurotech Begins Clinical Testing of Its Brain-Computer Interface System
2026-10-13 · Research
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Decode the Nervous System
2026-10-12 · Funding
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
Company details
Category
💙 Mental Health Tech
Location
New York, USA
Funding
Public · NASDAQ: SEEL
Website
seelosbio.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →